FUJIFILM Biotechnologies, a prominent contract development and manufacturing organization (CDMO), is currently navigating an unprecedented phase of strategic expansion, marked by approximately $7 billion in capital projects across its global network. This significant investment underscores the company’s commitment to scaling its biopharmaceutical manufacturing capabilities, addressing the burgeoning demand for complex biologics, and solidifying its position within the competitive CDMO landscape. At the helm of these transformative operational advancements is Maja Herold Pedersen, who transitioned to Chief Operating Officer in September 2025, bringing a unique perspective forged in quality assurance to the forefront of the company’s ambitious growth trajectory.
A Monumental Global Expansion Initiative
The cornerstone of FUJIFILM Biotechnologies’ expansion efforts is the state-of-the-art facility in Holly Springs, North Carolina. This site, representing a colossal $3.2 billion investment, saw its first phase become operational in September 2025, significantly boosting the company’s cell culture manufacturing capacity in the United States. A second phase for the Holly Springs site is projected to come online around 2028, further amplifying its capabilities. Industry analysts point to such large-scale investments as critical for meeting the increasing global demand for advanced biologics, including monoclonal antibodies, gene therapies, and cell therapies, which require specialized and high-volume production capacities. The U.S. biomanufacturing sector, in particular, has seen substantial growth, driven by both domestic innovation and strategic initiatives to strengthen pharmaceutical supply chain resilience.
Beyond the U.S., FUJIFILM Biotechnologies is simultaneously bolstering its European footprint. In Denmark, the company is expanding its Hillerød campus, adding eight new 20,000-liter bioreactors and two new downstream processing streams. This expansion in a key European biopharmaceutical hub is designed to enhance flexibility and capacity for larger-scale production, catering to both existing and new clients across the continent. Furthermore, early 2026 marked the opening of the United Kingdom’s largest single-use CDMO facility at Teesside. This facility leverages single-use technologies, which offer advantages in terms of reduced cross-contamination risks, faster changeovers between different products, and lower capital expenditure compared to traditional stainless steel facilities, making them increasingly popular in biomanufacturing for their efficiency and adaptability.
Complementing these large molecule expansions, FUJIFILM Cellular Dynamics, a sister subsidiary, inaugurated its new induced pluripotent stem cell (iPSC) manufacturing headquarters in Madison, Wisconsin, in May. This facility is part of a separate $200 million investment aimed at quadrupling the company’s cell-production capacity. The iPSC market is a rapidly evolving sector within regenerative medicine and drug discovery, holding immense promise for developing novel therapies for previously untreatable diseases. This investment positions FUJIFILM at the vanguard of scalable iPSC manufacturing, critical for translating groundbreaking research into clinical applications. The combined $7 billion investment across these sites reflects a strategic, diversified approach to dominating key segments of the biopharmaceutical manufacturing market.
Maja Herold Pedersen: From Quality Assurance to Operational Leadership
The orchestrator of this expansive operational buildout is Maja Herold Pedersen, whose career trajectory within FUJIFILM Biotechnologies offers a compelling narrative of leadership evolution. Her ascent to Chief Operating Officer in September 2025 followed a tenure as Chief Technology Officer and, prior to that, Chief Quality Officer. This progression from quality to operations is particularly insightful in a highly regulated industry like biopharmaceuticals. Pedersen emphasizes that her understanding of the complete picture, "how we get medicine to patients," has always guided her decisions, regardless of her specific role. "It doesn’t matter whether I’m wearing a quality hat or some other hat, we need to make this work for patients in the end," she stated in a recent interview, highlighting a patient-centric philosophy that permeates her leadership approach. This holistic view, originating from a deep understanding of regulatory requirements and patient safety, provides a strong foundation for managing complex operational challenges while ensuring product integrity and compliance.
Pedersen’s initial foray into quality and regulatory roles was serendipitous. Fresh from her master’s degree, she chose a path involving international travel and training in manufacturing quality systems over a PhD in research. This early exposure to the practicalities of Good Manufacturing Practices (GMP) and direct engagement with patient advocacy groups profoundly shaped her perspective. She gained an intimate understanding of patients’ daily struggles and what truly impacts their lives, imbuing her work with a sense of purpose that continues to drive her. This background, rooted in ensuring the highest standards of product safety and efficacy, now informs her strategic decisions in optimizing manufacturing processes and leveraging advanced technologies.
The "kojoX" Model: Standardizing Excellence
Central to FUJIFILM Biotechnologies’ strategy for integrating its vast biologics network is "kojoX," a proprietary modular bioproduction model. The name itself is a fusion of the Japanese word kojo (meaning "improvement" and "factory") and "X" for exponential scale, aptly describing its ambition. kojoX represents a paradigm shift in biomanufacturing, emphasizing standardized equipment, processes, and quality systems across all sites. This standardization is not merely about uniformity; it’s a strategic enabler for agility and efficiency. A validated drug-substance process developed at one site can be seamlessly transferred to an equivalent line anywhere else in the network. This capability dramatically compresses tech-transfer and regulatory timelines, which are traditionally significant bottlenecks in biopharmaceutical development and manufacturing.
The implications of kojoX are far-reaching. It enhances operational flexibility, allowing FUJIFILM Biotechnologies to respond quickly to client needs and market shifts. It also de-risks the manufacturing process by building redundancy and consistency across multiple locations. For clients, this means faster time-to-market for critical therapies and a more predictable development pathway. From a regulatory perspective, having standardized, validated systems simplifies compliance across different jurisdictions, potentially streamlining regulatory submissions and approvals.
Revolutionizing Operations with AI: The GenkiBot Initiative
One of Maja Herold Pedersen’s key mandates as COO is to accelerate the adoption and industrialization of Artificial Intelligence (AI) across FUJIFILM Biotechnologies’ highly regulated operations. Recognizing the inherent caution within the pharmaceutical industry towards novel technologies, Pedersen advocates for a proactive yet responsible approach. "In this industry, we have a tendency to think we can’t really do it, because we can’t validate it and we can’t verify it," she observes. However, she believes this shouldn’t hinder progress but rather compel the industry to move faster, albeit with careful human oversight.
Pedersen’s impatience with the status quo led to the in-house development of "GenkiBot," FUJIFILM’s proprietary ChatGPT-like tool. The name "Genki," a Japanese word associated with enthusiasm and positivity, reflects the aspirational nature of the initiative. Crucially, GenkiBot operates under FUJIFILM’s own security umbrella, addressing critical concerns about data privacy and intellectual property, which are paramount in the pharmaceutical sector. This strategic decision to build an internal AI platform was driven by the understanding that if internal solutions weren’t provided, employees would inevitably turn to external, less secure public AI tools.
GenkiBot is already demonstrating its utility in critical areas. A prime example is its application in deviation management, a notoriously time-consuming and complex process in manufacturing. The tool now assists in writing deviation reports, coaches subject matter experts (SMEs) on adherence to norms, and helps identify root causes beyond superficial explanations by analyzing available data. This not only streamlines documentation but also enhances the depth and accuracy of investigations, ultimately contributing to better quality outcomes. While currently used by roughly 50% of users handling deviations, Pedersen aims for 100% adoption, underscoring her commitment to embedding AI as a fundamental operational tool rather than an optional add-on.
Scaling AI Safely: The Challenge of Agentic Tools
The journey from pilot programs to full-scale AI integration in a regulated environment presents unique challenges, particularly concerning "agentic tools"—AI systems designed to perform tasks autonomously or semi-autonomously. Pedersen champions a somewhat unconventional approach to scaling AI: "I’m a big believer that scaling only follows the actual speed if we set it free." This philosophy suggests empowering a broader range of employees to develop and utilize AI agents, akin to the historical use of macros in Excel. The idea is to create a large funnel of coded agents, allowing the most effective and verifiable ones to be selected for integration into more controlled, GMP-critical environments. This "playful" and potentially "contradictory" approach, as Pedersen describes it, seeks to foster innovation and rapid development while maintaining stringent quality control for agents impacting critical GMP decisions.
Looking ahead, FUJIFILM Biotechnologies is exploring AI applications in tech transfers. This complex process, involving the transfer and organization of vast amounts of data into various documents for new product introductions, is ripe for AI-driven automation. Pedersen envisions agents capable of autonomously grabbing, organizing, and deploying data, significantly reducing the tedious manual effort involved and accelerating the onboarding of new technologies and products. The ability to expedite tech transfers would be a game-changer for CDMOs, allowing for quicker project initiation and enhanced client satisfaction. Regulatory bodies, such as the FDA and EMA, have begun issuing guidance on the responsible development and deployment of AI/ML in medical products, emphasizing data quality, transparency, and robust validation frameworks. This evolving regulatory landscape provides both guardrails and opportunities for companies like FUJIFILM Biotechnologies to innovate responsibly.
The "9 People Fundamentals": Fostering Autonomy and Accountability
Underpinning FUJIFILM Biotechnologies’ ambitious technological and operational advancements is a distinct corporate culture guided by its "9 People Fundamentals." This philosophy is rooted in the belief that empowering individuals to make decisions for which they are best placed can unlock immense energy and drive innovation. Pedersen likens the organization to a biological organism, where individual cells (employees) function effectively within a guiding "brain structure" (overall strategic direction). This approach aims to minimize bureaucratic hurdles and hierarchical bottlenecks, enabling rapid decision-making—a critical advantage in the fast-paced biopharma industry.
The fundamentals encapsulate principles such as leading people, managing processes, being one’s full self, empowerment, and accountability. The core idea is to instill a sense of ownership and capability in every employee, fostering an environment where individuals feel equipped and trusted to make impactful decisions. However, Pedersen acknowledges that this empowerment comes with a reciprocal demand for accountability. "Being empowered doesn’t come for free, quite the opposite," she notes.
To cultivate this mindset, FUJIFILM Biotechnologies is rolling out a "Leaders for Life cohort" for its leadership team. This program is designed to deepen leaders’ understanding of self-awareness, their reactions, and how these impact their surroundings. By fostering highly self-aware and responsible leaders, the company aims to create a culture where freedom and accountability coexist productively. This cultural emphasis on autonomy and responsibility is crucial for successfully integrating advanced technologies like AI, as it relies on employees’ initiative, critical thinking, and willingness to embrace new ways of working within a regulated framework. The feedback on this initiative has been positive, indicating a resonance within the organization for this forward-thinking approach to leadership and employee engagement.
Industry Implications and Future Outlook
FUJIFILM Biotechnologies’ multi-billion-dollar expansion, coupled with its proactive embrace of AI and a culture of empowerment, carries significant implications for the broader biopharmaceutical industry. The aggressive scaling of manufacturing capacity addresses a critical bottleneck in drug development, particularly for complex biologics and advanced therapies. As the global pipeline for these innovative medicines continues to grow, the demand for high-quality, flexible CDMO partners will only intensify. FUJIFILM’s strategic investments position it as a major player capable of meeting this escalating need, contributing to the overall resilience of the pharmaceutical supply chain.
The company’s leadership in integrating AI into regulated manufacturing processes also serves as a benchmark for the industry. By demonstrating practical applications in areas like deviation management and tech transfers, FUJIFILM Biotechnologies is helping to demystify AI’s role in biopharma and pave the way for broader adoption. The challenges of validating AI systems in a GMP environment are substantial, but Pedersen’s vision of "setting it free" while maintaining rigorous oversight could accelerate innovation. This blend of technological advancement and cultural transformation positions FUJIFILM Biotechnologies not just as a manufacturing partner, but as a thought leader in the evolution of modern biomanufacturing. The commitment to patient outcomes, a theme consistently articulated by Pedersen, remains the ultimate driver behind these strategic endeavors, aiming to bring life-changing medicines to those who need them most, faster and more reliably.
